American Association for Cancer Research
Browse
15417786mcr090460-sup-mink_et_al_supplementary_data_figs5.pdf (83.38 kB)

Supplementary Figures 1-5 from Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

Download (83.38 kB)
journal contribution
posted on 2023-04-03, 18:05 authored by Sheldon R. Mink, Surabhi Vashistha, Wenxuan Zhang, Amanda Hodge, David B. Agus, Anjali Jain
Supplementary Figures 1-5 from Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs

History

ARTICLE ABSTRACT

Epidermal growth factor receptor (EGFR) plays a critical role in oncogenesis, which makes it an attractive target for pharmacologic inhibition. Yet, EGFR inhibition with tyrosine kinase inhibitors (TKI) does not result in a measurable and sustainable clinical benefit in a vast majority of tumors. This emphasizes the need for further investigations into resistance mechanisms against EGFR-TKIs. We previously reported the generation of an in vivo adenocarcinoma model of EGFR-TKI–acquired resistance that was devoid of the known mechanisms of resistance. Using this same xenograft model, we now show that the tumor stroma plays an important role in limiting responsiveness to EGFR-TKIs. EGFR-TKI–resistant tumors display increased surface expression of CD44hi/CD24lo and markers of epithelial to mesenchymal transition (EMT), SNAI1, and N-cadherin. An in vivo green fluorescent protein–tagging approach reveals that the tumor stroma of the EGFR-TKI–resistant tumors is distinct in that 24% of its cancer-associated fibroblast (CAF) population is composed of EMT-derived tumor cells that represent the in vivo escape from EGFR-TKIs. We further show that EMT subpopulation–harboring CAFs isolated from the EGFR-TKI–resistant tumors are tumorigenic and express the biomarker of gefitinib resistance, epithelial membrane protein-1. Finally, we provide evidence that paracrine factors secreted from the EGFR-TKI–resistant CAFs mitigate the EGFR-TKI–mediated blockade of pEGFR and pMAPK in cocultured tumor cells, regardless of their EGFR mutational status. This is the first demonstration that the tumor stroma is modified with acquisition of EGFR-TKI resistance and that it further contributes in promoting drug resistance. Mol Cancer Res; 8(6); 809–20. ©2010 AACR.